ABCL · Annual Report (Form 10-K) · Filed February 24, 2026

Abcellera Biologics Inc — 10-K exhibit

abclfeb2026consent-10xk.htm

Abcellera Biologics Inc on Boardroom Alpha

abclfeb2026consent-10xk

Exhibit 23.1 Consent of Independent Registered Public Accounting Firm The Board of Directors AbCellera Biologics Inc. We consent to the use of: • our report dated February 24, 2026 on the consolidated financial statements of AbCellera Biologics Inc. (the “Entity”) which comprise the consolidated balance sheets as at December 31, 2025 and December 31, 2024, the related consolidated statements of loss and comprehensive loss, stockholders’ equity and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively the “consolidated financial statements”), and • our report dated February 24, 2026 on the effectiveness of the Entity’s internal control over financial reporting as of December 31, 2025 each of which is included in the Annual Report on Form 10-K of the Entity for the fiscal year ended December 31, 2025. We also consent to the incorporation by reference of such reports in the Registration Statements (Nos. 333-251341, 333-263025, 333-269896, 333-277192, and 333-285351) on Form S-8, and No. 333-285367 on Form S-3 of the Entity. /s/ KPMG LLP Chartered Professional Accountants February 24, 2026 Vancouver, Canada

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer